196 related articles for article (PubMed ID: 29141020)
21. Utility of p63 in the differential diagnosis of atypical fibroxanthoma and spindle cell squamous cell carcinoma.
Gleason BC; Calder KB; Cibull TL; Thomas AB; Billings SD; Morgan MB; Hiatt KM; Smoller BR
J Cutan Pathol; 2009 May; 36(5):543-7. PubMed ID: 19476522
[TBL] [Abstract][Full Text] [Related]
22. Study of Epithelial to Mesenchymal Transition in Atypical Fibroxanthoma and Undifferentiated Pleomorphic Sarcoma to Discern an Epithelial Origin.
Toll A; Gimeno J; Baró T; Hernández-Muñoz MI; Pujol RM
Am J Dermatopathol; 2016 Apr; 38(4):270-7. PubMed ID: 26999338
[TBL] [Abstract][Full Text] [Related]
23. [Atypical fibroxanthoma].
Vasilyev NV; Vtorushin SV; Maltseva AA; Sannikova AV
Arkh Patol; 2023; 85(5):65-72. PubMed ID: 37814853
[TBL] [Abstract][Full Text] [Related]
24. Atypical fibroxanthoma and pleomorphic dermal sarcoma - gene expression analysis compared with undifferentiated cutaneous squamous cell carcinoma.
Anders IM; Schimmelpfennig C; Wiedemann K; Löffler D; Kämpf C; Blumert C; Reiche K; Kunz M; Anderegg U; Simon JC; Ziemer M
J Dtsch Dermatol Ges; 2023 May; 21(5):482-491. PubMed ID: 37035902
[TBL] [Abstract][Full Text] [Related]
25. Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis.
Pastushenko I; Mauri F; Song Y; de Cock F; Meeusen B; Swedlund B; Impens F; Van Haver D; Opitz M; Thery M; Bareche Y; Lapouge G; Vermeersch M; Van Eycke YR; Balsat C; Decaestecker C; Sokolow Y; Hassid S; Perez-Bustillo A; Agreda-Moreno B; Rios-Buceta L; Jaen P; Redondo P; Sieira-Gil R; Millan-Cayetano JF; Sanmatrtin O; D'Haene N; Moers V; Rozzi M; Blondeau J; Lemaire S; Scozzaro S; Janssens V; De Troya M; Dubois C; Pérez-Morga D; Salmon I; Sotiriou C; Helmbacher F; Blanpain C
Nature; 2021 Jan; 589(7842):448-455. PubMed ID: 33328637
[TBL] [Abstract][Full Text] [Related]
26. CD117 immunoreactivity in atypical fibroxanthoma.
Mathew RA; Schlauder SM; Calder KB; Morgan MB
Am J Dermatopathol; 2008 Feb; 30(1):34-6. PubMed ID: 18212542
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical Characteristics of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma: A Systematic Review and Meta-Analysis.
Ørholt M; Abebe K; Aaberg F; Rasmussen LE; Daugaard S; Loya AC; Herly M; Vester-Glowinski PV
Am J Dermatopathol; 2022 Dec; 44(12):913-920. PubMed ID: 36395448
[TBL] [Abstract][Full Text] [Related]
28.
Gaiser T; Hirsch D; Orouji A; Bach M; Kind P; Helbig D; Quaas A; Utikal J; Marx A; Gaiser MR
Oncotarget; 2018 Apr; 9(30):21182-21189. PubMed ID: 29765529
[TBL] [Abstract][Full Text] [Related]
29. Mutant collagen COL11A1 enhances cancerous invasion.
Lee CS; Siprashvili Z; Mah A; Bencomo T; Elcavage LE; Che Y; Shenoy RM; Aasi SZ; Khavari PA
Oncogene; 2021 Nov; 40(44):6299-6307. PubMed ID: 34584216
[TBL] [Abstract][Full Text] [Related]
30. Atypical fibroxanthoma management: Recurrence, metastasis and disease-specific death.
Polcz MM; Sebaratnam DF; Fernández-Peñas P
Australas J Dermatol; 2018 Feb; 59(1):10-25. PubMed ID: 28815551
[TBL] [Abstract][Full Text] [Related]
31. Atypical fibroxanthoma and malignant fibrous histiocytoma of the skin.
Rizzardi C; Angiero F; Melato M
Anticancer Res; 2003; 23(2C):1847-51. PubMed ID: 12820468
[TBL] [Abstract][Full Text] [Related]
32. Atypical fibroxanthoma.
Sakamoto A
Clin Med Oncol; 2008; 2():117-27. PubMed ID: 21892274
[TBL] [Abstract][Full Text] [Related]
33. Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.
Cho SY; Choi M; Ban HJ; Lee CH; Park S; Kim H; Kim YS; Lee YS; Lee JY
Oncotarget; 2017 Jan; 8(5):8095-8104. PubMed ID: 28042953
[TBL] [Abstract][Full Text] [Related]
34. Genomic and Transcriptomic Characterization of Sporadic Medullary Thyroid Carcinoma.
Qu N; Shi X; Zhao JJ; Guan H; Zhang TT; Wen SS; Liao T; Hu JQ; Liu WY; Wang YL; Huang S; Shi RL; Wang Y; Ji QH
Thyroid; 2020 Jul; 30(7):1025-1036. PubMed ID: 32031055
[No Abstract] [Full Text] [Related]
35. Evaluation of CD10 and procollagen 1 expression in atypical fibroxanthoma and dermatofibroma.
de Feraudy S; Mar N; McCalmont TH
Am J Surg Pathol; 2008 Aug; 32(8):1111-22. PubMed ID: 18545147
[TBL] [Abstract][Full Text] [Related]
36. Atypical fibroxanthoma: DNA ploidy analysis of 14 cases with possible histogenetic implications.
Worrell JT; Ansari MQ; Ansari SJ; Cockerell CJ
J Cutan Pathol; 1993 Jun; 20(3):211-5. PubMed ID: 8396160
[TBL] [Abstract][Full Text] [Related]
37. Novel somatic alterations underlie Chinese papillary thyroid carcinoma.
Yang C; Xu W; Gong J; Liu Z; Cui D
Cancer Biomark; 2020; 27(4):445-460. PubMed ID: 32065787
[TBL] [Abstract][Full Text] [Related]
38. Atypical Fibroxanthoma Revisited.
Mentzel T; Requena L; Brenn T
Surg Pathol Clin; 2017 Jun; 10(2):319-335. PubMed ID: 28477883
[TBL] [Abstract][Full Text] [Related]
39. Targeted next-generation sequencing of matched localized and metastatic primary high-risk SCCs identifies driver and co-occurring mutations and novel therapeutic targets.
Lobl MB; Clarey D; Higgins S; Sutton A; Hansen L; Wysong A
J Dermatol Sci; 2020 Jul; 99(1):30-43. PubMed ID: 32595073
[TBL] [Abstract][Full Text] [Related]
40. Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.
Ali NM; Niada S; Brini AT; Morris MR; Kurusamy S; Alholle A; Huen D; Antonescu CR; Tirode F; Sumathi V; Latif F
J Pathol; 2019 Feb; 247(2):166-176. PubMed ID: 30281149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
